GeneDx Holdings Corp. (WGS) stock
WGSNasdaqServices-Health ServicesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3058% above fair value
$51.02−1.35 (-2.58%)
Close on Nov 16, 2026Market cap $1.52BP/E –Yield –
GeneDx total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
GeneDx's total debt was $96.84M at Jun 30, 2026. For fiscal 2025 it was $52.72M, down 0.8% from the year before. The highest annual figure on record is $53.19M in fiscal 2023.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.72M | -0.8% |
| FY2024 | Dec 31, 2024 | $53.12M | -0.1% |
| FY2023 | Dec 31, 2023 | $53.19M | +383.5% |
| FY2022 | Dec 31, 2022 | $11.00M | 0.0% |
| FY2021 | Dec 31, 2021 | $11.00M | -47.0% |
| FY2020 | Dec 31, 2020 | $20.74M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $96.84M | +83.0% |
| Q1 FY2026 | Mar 31, 2026 | $96.73M | +82.5% |
| Q4 FY2025 | Dec 31, 2025 | $52.72M | -0.8% |
| Q3 FY2025 | Sep 30, 2025 | $52.81M | -0.8% |
| Q2 FY2025 | Jun 30, 2025 | $52.91M | -0.7% |
| Q1 FY2025 | Mar 31, 2025 | $53.01M | -0.2% |
| Q4 FY2024 | Dec 31, 2024 | $53.12M | -0.1% |
| Q3 FY2024 | Sep 30, 2024 | $53.24M | +751.8% |
| Q2 FY2024 | Jun 30, 2024 | $53.26M | +752.2% |
| Q1 FY2024 | Mar 31, 2024 | $53.09M | +749.5% |
| Q4 FY2023 | Dec 31, 2023 | $53.19M | +383.5% |
| Q3 FY2023 | Sep 30, 2023 | $6.25M | -43.2% |
| Q2 FY2023 | Jun 30, 2023 | $6.25M | -43.2% |
| Q1 FY2023 | Mar 31, 2023 | $6.25M | -43.2% |
| Q4 FY2022 | Dec 31, 2022 | $11.00M | 0.0% |
| Q3 FY2022 | Sep 30, 2022 | $11.00M | 0.0% |
| Q2 FY2022 | Jun 30, 2022 | $11.00M | -39.0% |
| Q1 FY2022 | Mar 31, 2022 | $11.00M | -40.5% |
| Q4 FY2021 | Dec 31, 2021 | $11.00M | -47.0% |
| Q3 FY2021 | Sep 30, 2021 | $11.00M | – |
| Q2 FY2021 | Jun 30, 2021 | $18.03M | – |
| Q1 FY2021 | Mar 31, 2021 | $18.50M | – |
| Q4 FY2020 | Dec 31, 2020 | $20.74M | – |
See a number that looks wrong?